Global Acute Myeloid Leukemia Market Report 2024

Acute Myeloid Leukemia Global Market Report 2024 – By Treatment Type (Chemotherapy, Radiation therapy, Stem Cell Transplant, Targeted Therapy), By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy), By Regimen (DC Regimen, AVD Regimen, VCD Regimen), By End-User (Hospital, Retails Drug Stores, Ambulatory Care Centers, Clinics) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 200 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Acute Myeloid Leukemia Market

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Acute Myeloid Leukemia Market Definition And Segments

Acute myeloid leukemia (AML) is a type of blood cancer that occurs due to abnormal white blood cell in bone marrow. Myeloblasts, also known as leukemic blasts, or excessive production of immature white blood cells, are the hallmark of AML. The bone marrow is crowded with these cells, which stops it from producing healthy blood cells.

The main acute myeloid leukemia treatment types include chemotherapy, radiation therapy, stem cell transplant, and targeted therapy. Chemotherapy is a drug treatment that uses powerful chemicals to kill fast-growing cells in the body. The different acute myeloid leukemia chemotherapies include cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, and hormonal therapy. They are of various regimens such as DC regimen, AVD regimen, and VCD regimen. Acute myeloid leukemia is treated by different end-users such as hospitals, retail drug stores, ambulatory care centers, and clinics.

The acute myeloid leukemia market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Radiation therapy, Stem Cell Transplant, Targeted Therapy

2) By Chemotherapy: Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy

3) By Regimen: DC Regimen, AVD Regimen, VCD Regimen

4) By End-User: Hospital, Retails Drug Stores, Ambulatory Care Centers, Clinics

The acute myeloid leukemia market size has grown strongly in recent years. It will grow from $2.21 billion in 2023 to $2.39 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to growth aging population, environmental factors, genetic predisposition, limited treatment options, medical advancements.

The acute myeloid leukemia market size is expected to see strong growth in the next few years. It will grow to $3.21 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to growing advancements in targeted therapies, immunotherapies development, precision medicine approaches, increased awareness and early detection, collaborative research initiatives. Major trends in the forecast period include emphasis on minimal residual disease monitoring, integration of artificial intelligence (ai) in treatment decision support, focus on supportive care and quality of life interventions, collaborative research initiatives and clinical trials, patient advocacy and empowerment programs.

Geriatric Population And Unmet Healthcare Needs Fuel Growth In Acute Myeloid Leukemia Market

The increase in the older population base and growing unmet healthcare needs is expected to propel the growth of the acute myeloid leukemia market over the coming years. The geriatric population and growing unmet healthcare are defined as the elderly population, people aged 65 and over suffering from health issues like acute myeloid leukemia. For instance, according to the American Cancer Society USA (ACS), a nationwide voluntary health organization, in 2022, AML was commonly found in elderly people with an average age at diagnosis being 68, and survival of elderly AML patients remained remarkably low. It affected approximately 60,650 people in 2022 and caused 24000 deaths. Therefore, the geriatric population base and growing unmet healthcare needs drive the gelatin market.

Rising Adoption Of Personalized Medicine To Drive Market Growth

The increasing adoption of personalized medicine is expected to propel the growth of acute myeloid leukemia market going forward. Personalized medicine is an innovative approach to medical treatment and healthcare that considers individual differences in patients' genes, environments, and lifestyles. In acute myeloid leukemia (AML), personalized medicine is employed through molecular profiling to identify specific genetic mutations and biomarkers unique to individual patients. This information guides the selection of targeted therapies and tailored treatment plans, optimizing the effectiveness of interventions while minimizing adverse effects for a more personalized and precise approach to AML management. For instance, in 2022, according to the Personalized Medicine Coalition, a US-based professional membership organization, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022. Out of the 35 therapeutic NMEs, approximately 34%, which amounts to 12 of them, are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Therefore, the increasing adoption of personalized medicine is driving the growth of acute myeloid leukemia market.

Major companies operating in the acute myeloid leukemia market report are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi-Aventis (Genzyme Corporation), Bristol Myers Squibb Company, GlaxoSmithKline PLC, Takeda Pharmaceuticals, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical, Celgene Corporation, Astellas Pharma, Servier Pharmaceuticals, CSPC Pharmaceutical Group, Genmab AS, Zhejiang Medicine Co. Ltd., Syndax Pharmaceuticals Inc., Astex Pharmaceuticals Inc., MEI Pharma Inc., SELLAS Life Sciences Group, Ambit Biosciences Corporation, Agios Pharmaceuticals Inc., Neomed Management AS, Oncolyze Inc., TC BioPharm, VERASTEM INC., Mirati Therapeutics Inc., Sunshine Lake Pharma, Sunesis Pharmaceuticals Inc.

Innovative Research And Development Initiatives Transforming The Acute Myeloid Leukemia Market

Growing investments in R&D using the pharmaceutical groups are a key trend gaining popularity in the acute myeloid leukemia market. R&D is used to develop new and improved products and services to fulfill the needs of drug development. For instance, in May 2022, according to National Library of Medicine, a US-based national medical library, a study with the title ‘Daunorubicin or Idarubicin with Cytarabine Plus Quizartinib vs. Physician's Choice in Newly Diagnosed FLT3-ITD+ AML (Q-SOC)’ is in Phase III of clinical trials. It commenced in November 2021 and is expected to conclude by March 2025.

Pharmaceutical Companies Enhancing Acute Myeloid Leukemia Treatment Armamentarium With Quizartinib Approval

Major companies operating in the acute myeloid leukemia markets are focused on developing advanced drug solutions such as maintenance monotherapy to expand their product portfolios to improve patient outcomes and address unmet medical needs. Maintenance monotherapy refers to a medical treatment approach where a single therapeutic agent is administered to a patient as an ongoing, long-term therapy to prevent the recurrence or progression of a medical condition. For instance, in July 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, received United States Food and Drug Administration (USFDA) approval for quizartinib (Vanflyta) in combination with standard cytarabine and anthracycline induction, followed by cytarabine consolidation, and as maintenance monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults with FLT3 internal tandem duplication (ITD)-positive status, as determined by an FDA-approved test. The LeukoStrat CDx FLT3 Mutation Assay has also been approved as a companion diagnostic for Vanflyta. The approval is based on positive results from the QuANTUM-First trial, showing a statistically significant improvement in overall survival for patients receiving quizartinib compared to a placebo. Quizartinib's recommended dosage varies during induction, consolidation, and maintenance phases. The drug is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation.

Qiagen And Servier Collaborate To Develop Companion Diagnostic Test For AML Treatment

In March 2023, QIAGEN, a Netherlands-based biotechnology company, partnered with Servier Laboratories, for an undisclosed amount. This partnership aims to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor intended for treating acute myeloid leukemia (AML). Under this Master Collaboration Agreement, QIAGEN will create and validate a real-time in vitro PCR test designed to detect IDH1 gene mutations in AML patients using blood and bone marrow samples. This collaboration enhances the global accessibility of TIBSOVO for AML patients with IDH1 mutations and reinforces QIAGEN's role in developing companion diagnostics for emerging biomarkers in onco-hematology, furthering precision medicine initiatives. Servier Laboratories, a France-based pharmaceutical company

North America was the largest region in the acute myeloid leukemia market in 2023. The regions covered in the acute myeloid leukemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acute myeloid leukemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The acute myeloid leukemia market includes revenue earned by drugs such as DC regimen, AVD Regimen, VCD regimen, cytarabine, vidaza, dacogen, midostaurin, quizartinib, vosaroxin that are used for the treatment of acute myeloid leukemia. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The acute myeloid leukemia market research report is one of a series of new reports from The Business Research Company that provides acute myeloid leukemia market statistics, including acute myeloid leukemia industry global market size, regional shares, competitors with a acute myeloid leukemia market share, detailed acute myeloid leukemia market segments, market trends and opportunities, and any further data you may need to thrive in the acute myeloid leukemia industry. This acute myeloid leukemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute Myeloid Leukemia Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $2.39 billion
Revenue Forecast In 2033 $3.21 billion
Growth Rate CAGR of 7.6% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Treatment Type: Chemotherapy, Radiation therapy, Stem Cell Transplant, Targeted Therapy
2) By Chemotherapy: Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy
3) By Regimen: DC Regimen, AVD Regimen, VCD Regimen
4) By End-User: Hospital, Retails Drug Stores, Ambulatory Care Centers, Clinics
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Pfizer Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Novartis AG; Sanofi-Aventis (Genzyme Corporation); Bristol Myers Squibb Company; GlaxoSmithKline plc; Takeda Pharmaceuticals; Amgen Inc.; Otsuka Holdings Co. Ltd.; Teva Pharmaceutical; Celgene Corporation; Astellas Pharma; Servier Pharmaceuticals; CSPC Pharmaceutical Group; Genmab AS; Zhejiang Medicine Co. Ltd.; Syndax Pharmaceuticals Inc.; Astex Pharmaceuticals Inc.; MEI Pharma Inc.; SELLAS Life Sciences Group; Ambit Biosciences Corporation; Agios Pharmaceuticals Inc.; Neomed Management AS; Oncolyze Inc.; TC BioPharm; VERASTEM INC.; Mirati Therapeutics Inc.; Sunshine Lake Pharma; Sunesis Pharmaceuticals Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Acute Myeloid Leukemia Market Characteristics

    3. Acute Myeloid Leukemia Market Trends And Strategies

    4. Acute Myeloid Leukemia Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Acute Myeloid Leukemia Market Size and Growth

    5.1. Global Acute Myeloid Leukemia Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Acute Myeloid Leukemia Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Acute Myeloid Leukemia Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Acute Myeloid Leukemia Market Segmentation

    6.1. Global Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Chemotherapy

    Radiation therapy

    Stem Cell Transplant

    Targeted Therapy

    6.2. Global Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Cytarabine

    Anthracycline Drugs

    Alkylating Agents

    Anti-metabolites

    Tyrosine Kinase Inhibitors

    Hormonal Therapy

    6.3. Global Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    DC Regimen

    AVD Regimen

    VCD Regimen

    6.4. Global Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital

    Retails Drug Stores

    Ambulatory Care Centers

    Clinics

    7. Acute Myeloid Leukemia Market Regional And Country Analysis

    7.1. Global Acute Myeloid Leukemia Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Acute Myeloid Leukemia Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Acute Myeloid Leukemia Market

    8.1. Asia-Pacific Acute Myeloid Leukemia Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Acute Myeloid Leukemia Market

    9.1. China Acute Myeloid Leukemia Market Overview

    9.2. China Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Acute Myeloid Leukemia Market

    10.1. India Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Acute Myeloid Leukemia Market

    11.1. Japan Acute Myeloid Leukemia Market Overview

    11.2. Japan Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Acute Myeloid Leukemia Market

    12.1. Australia Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Acute Myeloid Leukemia Market

    13.1. Indonesia Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Acute Myeloid Leukemia Market

    14.1. South Korea Acute Myeloid Leukemia Market Overview

    14.2. South Korea Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Acute Myeloid Leukemia Market

    15.1. Western Europe Acute Myeloid Leukemia Market Overview

    15.2. Western Europe Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Acute Myeloid Leukemia Market

    16.1. UK Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Acute Myeloid Leukemia Market

    17.1. Germany Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Acute Myeloid Leukemia Market

    18.1. France Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Acute Myeloid Leukemia Market

    19.1. Italy Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Acute Myeloid Leukemia Market

    20.1. Spain Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Acute Myeloid Leukemia Market

    21.1. Eastern Europe Acute Myeloid Leukemia Market Overview

    21.2. Eastern Europe Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Acute Myeloid Leukemia Market

    22.1. Russia Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Acute Myeloid Leukemia Market

    23.1. North America Acute Myeloid Leukemia Market Overview

    23.2. North America Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Acute Myeloid Leukemia Market

    24.1. USA Acute Myeloid Leukemia Market Overview

    24.2. USA Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Acute Myeloid Leukemia Market

    25.1. Canada Acute Myeloid Leukemia Market Overview

    25.2. Canada Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Acute Myeloid Leukemia Market

    26.1. South America Acute Myeloid Leukemia Market Overview

    26.2. South America Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Acute Myeloid Leukemia Market

    27.1. Brazil Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Acute Myeloid Leukemia Market

    28.1. Middle East Acute Myeloid Leukemia Market Overview

    28.2. Middle East Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Acute Myeloid Leukemia Market

    29.1. Africa Acute Myeloid Leukemia Market Overview

    29.2. Africa Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Acute Myeloid Leukemia Market Competitive Landscape And Company Profiles

    30.1. Acute Myeloid Leukemia Market Competitive Landscape

    30.2. Acute Myeloid Leukemia Market Company Profiles

    30.2.1. Pfizer Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. F. Hoffmann-La Roche AG

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. AbbVie Inc.

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Novartis AG

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Sanofi-Aventis (Genzyme Corporation)

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Acute Myeloid Leukemia Market Other Major And Innovative Companies

    31.1. Bristol Myers Squibb Company

    31.2. GlaxoSmithKline plc

    31.3. Takeda Pharmaceuticals

    31.4. Amgen Inc.

    31.5. Otsuka Holdings Co. Ltd.

    31.6. Teva Pharmaceutical

    31.7. Celgene Corporation

    31.8. Astellas Pharma

    31.9. Servier Pharmaceuticals

    31.10. CSPC Pharmaceutical Group

    31.11. Genmab AS

    31.12. Zhejiang Medicine Co. Ltd.

    31.13. Syndax Pharmaceuticals Inc.

    31.14. Astex Pharmaceuticals Inc.

    31.15. MEI Pharma Inc.

    32. Global Acute Myeloid Leukemia Market Competitive Benchmarking

    33. Global Acute Myeloid Leukemia Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Acute Myeloid Leukemia Market

    35. Acute Myeloid Leukemia Market Future Outlook and Potential Analysis

    35.1 Acute Myeloid Leukemia Market In 2028 - Countries Offering Most New Opportunities

    35.2 Acute Myeloid Leukemia Market In 2028 - Segments Offering Most New Opportunities

    35.3 Acute Myeloid Leukemia Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Acute Myeloid Leukemia Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Global Acute Myeloid Leukemia Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: Asia-Pacific, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: China, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: India, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Japan, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Australia, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: Indonesia, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: South Korea, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: Western Europe, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: UK, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: Germany, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: France, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Italy, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Spain, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Eastern Europe, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: Russia, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: North America, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: USA, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: Canada, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: South America, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Brazil, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Middle East, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Africa, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 75: Pfizer Inc. Financial Performance
  • Table 76: F. Hoffmann-La Roche AG Financial Performance
  • Table 77: AbbVie Inc. Financial Performance
  • Table 78: Novartis AG Financial Performance
  • Table 79: Sanofi-Aventis (Genzyme Corporation) Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Acute Myeloid Leukemia Market, Segmentation By Regimen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Acute Myeloid Leukemia Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Global Acute Myeloid Leukemia Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: Asia-Pacific, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: China, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: India, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Japan, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Australia, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: Indonesia, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: South Korea, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: Western Europe, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: UK, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: Germany, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: France, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Italy, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Spain, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Eastern Europe, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: Russia, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: North America, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: USA, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: Canada, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: South America, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Brazil, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Middle East, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Acute Myeloid Leukemia Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Acute Myeloid Leukemia Market, Segmentation By Chemotherapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Africa, Acute Myeloid Leukemia Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 75: Pfizer Inc. Financial Performance
  • Figure 76: F. Hoffmann-La Roche AG Financial Performance
  • Figure 77: AbbVie Inc. Financial Performance
  • Figure 78: Novartis AG Financial Performance
  • Figure 79: Sanofi-Aventis (Genzyme Corporation) Financial Performance
Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis
Read More
How Will The Nuclear Medicine Market Grow In 2022?
Read More
What Is The Pediatric Imaging Market Overview In 2022?
Read More
Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth
Read More
Pain Management Devices And Therapies Global Market Report 2024 – By Type (Electrical Stimulators, Ablation Devices, Neurostimulators, Analgesic Pumps), By Neurostimulation Devices (Spinal Cord Stimulation (SCS) Devices, Deep Brain Stimulation Devices, Vagus Nerve Stimulation Devices, Sacral Nerve Stimulation Devices), By Electrical Stimulation Devices (Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Neuromuscular Electrical Stimulation (NMES/EMS) Devices, Combination Devices, Electrotherapy Devices, TNS), By Ablation Devices (Radiofrequency Ablation Devices, Cryoablation Devices), By Analgesic Infusion Pumps (Intrathecal Infusion Pumps, External Infusion Pumps), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, Trauma) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Metabolomics Global Market Report 2024 – By Product & Service (Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services), By Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors of Metabolism, Other Indications), By Application (Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics, Personalized Medicine, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024 – By Product (Instrument, Reagent), By Technology (NASBA, HAD), By Application (Blood Screening, Infectious Disease Diagnostics, Cancer), By End-User (Hospital, Reference Laboratories, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Monoclonal Antibodies (MAs) Global Market Report 2024 – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications), By End Users (Hospitals, Private Clinics, Research Institute) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Cancer biologics Global Market Report 2024 – By Type (Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types), By Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications), By Distribution Channel (Hospitals, Clinics, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Skin Cancer Drugs Global Market Report 2024 – By Type (Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma), By Drug Class (Chemotherapy, Immunotherapy, Targeted Agents & Other Drugs), By End Users (Hospitals, Cancer Research Centers, Clinics) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Pancreatic Cancer Drugs Global Market Report 2024 – By Type (Pancreatic Neuroendocrine Cancer Drugs, Pancreatic Exocrine Cancer Drugs), By Drug Combination (Single, Double, Triplet, Quadruplet), By End User (Hospital Pharmacies, Retail Pharmacies, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Lung Cancer Drugs Global Market Report 2024 – By Drugs (Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs), By Disease Type (Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)), By End User (Hospitals, Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the acute myeloid leukemia market?

Acute myeloid leukemia (AML) is a type of blood cancer that occurs due to abnormal white blood cell in bone marrow. Myeloblasts, also known as leukaemic blasts, or excessive production of immature white blood cells, are the hallmark of AML. The bone marrow is crowded with these cells, which stops it from producing healthy blood cells. For further insights on the acute myeloid leukemia market, request a sample here

How will the acute myeloid leukemia market drivers and restraints affect the acute myeloid leukemia market dynamics? What forces will shape the acute myeloid leukemia industry going forward?

The acute myeloid leukemia market growth is aided by geriatric population base and growing unmet healthcare needs. For further insights on the acute myeloid leukemia market, request a sample here

What is the forecast market size or the forecast market value of the acute myeloid leukemia market?

The acute myeloid leukemia market is expected to reach $2.03 billion in 2027 at a rate of 12.03%. For further insights on the acute myeloid leukemia market, request a sample here

How is the acute myeloid leukemia market segmented?

The global acute myeloid leukemia market is segmented as
1) By Treatment Type: Chemotherapy, Radiation therapy, Stem Cell Transplant, Targeted Therapy
2) By Chemotherapy: Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy
3) By Regimen: DC Regimen, AVD Regimen, VCD Regimen
4) By End-User: Hospital, Retails Drug Stores, Ambulatory Care Centers, Clinics
For further insights on the acute myeloid leukemia market, request a sample here

Which region has the largest share of the acute myeloid leukemia market? What are the largest region's market size and growth rate?

North America was the largest region in the acute myeloid leukemia market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Who are the major players in the acute myeloid leukemia market?

Key competitors in the acute myeloid leukemia market are, Pfizer Inc., Novartis AG, Sanofi-Aventis (Genzyme Corporation), Bristol Myers Squibb , Amgen Inc., Celgene Corporation, Ambit Biosciences Corporation, Takeda Pharmaceuticals. For further insights on the acute myeloid leukemia market, request a sample here.

What are the key trends in the acute myeloid leukemia market?

Major trends influencing the acute myeloid leukemia market include growing investments in R&D using the pharmaceutical groups. R&D is used to develop new and improved products and services to fulfill the needs of drug development. For further insights on the acute myeloid leukemia, request a sample here.

What are the major opportunities in the acute myeloid leukemia market? What are the strategies for the acute myeloid leukemia market?

For detailed insights on the major opportunities and strategies in the acute myeloid leukemia market, request a sample here.

How does the acute myeloid leukemia market relate to the overall economy and other similar markets?

For detailed insights on acute myeloid leukemia market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the acute myeloid leukemia industry?

For detailed insights on the mergers and acquisitions in the acute myeloid leukemia industry, request a sample here.

What are the key dynamics influencing the acute myeloid leukemia market growth? SWOT analysis of the acute myeloid leukemia market.

For detailed insights on the key dynamics influencing the acute myeloid leukemia market growth and SWOT analysis of the acute myeloid leukemia industry, request a sample here.